References
[1] C. J. Tann et al., “Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 65, no. suppl_2, pp. S173–S189, Nov. 2017, doi: 10.1093/cid/cix662.
[2] “Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion Summary, Number 797,” Obstet. Gynecol., vol. 135, no. 2, pp. 489–492, Feb. 2020, doi: 10.1097/AOG.0000000000003669.
[3] J. A. Morgan, N. Zafar, and D. B. Cooper, “Group B Streptococcus And Pregnancy,” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2022. Accessed: Jan. 20, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK482443/
[4] S. A. Nanduri et al., “Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance,” JAMA Pediatr., vol. 173, no. 3, pp. 224–233, Mar. 2019, doi: 10.1001/jamapediatrics.2018.4826.
[5] “Overview | Caesarean birth | Guidance | NICE.” Accessed: Jan. 20, 2022. [Online]. Available: https://www.nice.org.uk/guidance/ng192
[6] Committee on Practice Bulletins-Obstetrics, “ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery,” Obstet. Gynecol., vol. 132, no. 3, pp. e103–e119, Sep. 2018, doi: 10.1097/AOG.0000000000002833.
[7] S. A. Sullivan, T. Smith, E. Chang, T. Hulsey, J. P. Vandorsten, and D. Soper, “Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized, controlled trial,” Am. J. Obstet. Gynecol., vol. 196, no. 5, p. 455.e1–5, May 2007, doi: 10.1016/j.ajog.2007.03.022.
[8] N. Bhattacharjee, S. P. Saha, K. K. Patra, U. Mitra, and S. C. Ghoshroy, “Optimal timing of prophylactic antibiotic for cesarean delivery: a randomized comparative study,” J. Obstet. Gynaecol. Res., vol. 39, no. 12, pp. 1560–1568, Dec. 2013, doi: 10.1111/jog.12102.
[9] L. D. Dlamini et al., “Antibiotic prophylaxis for caesarean section at a Ugandan hospital: a randomised clinical trial evaluating the effect of administration time on the incidence of postoperative infections,” BMC Pregnancy Childbirth, vol. 15, p. 91, Apr. 2015, doi: 10.1186/s12884-015-0514-3.
[10] C. A. Jyothirmayi, A. Halder, B. Yadav, S. T. Samuel, A. Kuruvilla, and R. Jose, “A randomized controlled double blind trial comparing the effects of the prophylactic antibiotic, Cefazolin, administered at caesarean delivery at two different timings (before skin incision and after cord clamping) on both the mother and newborn,” BMC Pregnancy Childbirth, vol. 17, no. 1, p. 340, Oct. 2017, doi: 10.1186/s12884-017-1526-y.
[11] B. D. Thigpen et al., “Timing of prophylactic antibiotic administration in the uninfected laboring gravida: a randomized clinical trial,” Am. J. Obstet. Gynecol., vol. 192, no. 6, pp. 1864–1868; discussion 1868-1871, Jun. 2005, doi: 10.1016/j.ajog.2004.12.063.
[12] J. R. Wax et al., “Single dose cefazolin prophylaxis for postcesarean infections: before vs. after cord clamping,” J. Matern. Fetal Med., vol. 6, no. 1, pp. 61–65, Feb. 1997, doi: 10.1002/(SICI)1520-6661(199701/02)6:1<61::AID-MFM13>3.0.CO;2-P.
[13] G. Yildirim et al., “When should we perform prophylactic antibiotics in elective cesarean cases?,” Arch. Gynecol. Obstet., vol. 280, no. 1, pp. 13–18, Jul. 2009, doi: 10.1007/s00404-008-0845-7.
[14] A. Witt et al., “Antibiotic prophylaxis before surgery vs after cord clamping in elective cesarean delivery: a double-blind, prospective, randomized, placebo-controlled trial,” Arch. Surg. Chic. Ill 1960, vol. 146, no. 12, pp. 1404–1409, Dec. 2011, doi: 10.1001/archsurg.2011.725.
[15] R. Sommerstein et al., “Antimicrobial prophylaxis administration after umbilical cord clamping in cesarean section and the risk of surgical site infection: a cohort study with 55,901 patients,” Antimicrob. Resist. Infect. Control, vol. 9, no. 1, p. 201, Dec. 2020, doi: 10.1186/s13756-020-00860-0.
[16] T. Dierikx et al., “Influence of timing of maternal antibiotic administration during caesarean section on infant microbial colonisation: a randomised controlled trial,” Gut, p. gutjnl-2021-324767, Nov. 2021, doi: 10.1136/gutjnl-2021-324767.
[17] S. S. Kamal et al., “Impact of Early Exposure to Cefuroxime on the Composition of the Gut Microbiota in Infants Following Cesarean Delivery,” J. Pediatr., vol. 210, pp. 99-105.e2, Jul. 2019, doi: 10.1016/j.jpeds.2019.03.001.
[18] R. Romero et al., “Clinical chorioamnionitis at term X: microbiology, clinical signs, placental pathology, and neonatal bacteremia - implications for clinical care,” J. Perinat. Med., vol. 49, no. 3, pp. 275–298, Mar. 2021, doi: 10.1515/jpm-2020-0297.
[19] C. J. Kim, R. Romero, P. Chaemsaithong, N. Chaiyasit, B. H. Yoon, and Y. M. Kim, “Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance,” Am. J. Obstet. Gynecol., vol. 213, no. 4 Suppl, pp. S29-52, Oct. 2015, doi: 10.1016/j.ajog.2015.08.040.
[20] “Intrapartum Management of Intraamniotic Infection.” Accessed: Sep. 25, 2023. [Online]. Available: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/intrapartum-management-of-intraamniotic-infection
[21] M. B. Azad et al., “Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study,” BJOG Int. J. Obstet. Gynaecol., vol. 123, no. 6, pp. 983–993, May 2016, doi: 10.1111/1471-0528.13601.
[22] S. Ainonen et al., “Antibiotics at birth and later antibiotic courses: effects on gut microbiota,” Pediatr. Res., Apr. 2021, doi: 10.1038/s41390-021-01494-7.
[23] J. E. Koenig et al., “Succession of microbial consortia in the developing infant gut microbiome,” Proc. Natl. Acad. Sci. U. S. A., vol. 108 Suppl 1, pp. 4578–4585, Mar. 2011, doi: 10.1073/pnas.1000081107.
[24] Y. Y. Chen et al., “Impact of Maternal Intrapartum Antibiotics, and Caesarean Section with and without Labour on Bifidobacterium and Other Infant Gut Microbiota,” Microorganisms, vol. 9, no. 9, p. 1847, Aug. 2021, doi: 10.3390/microorganisms9091847.
[25] A. Nogacka et al., “Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates,” Microbiome, vol. 5, no. 1, p. 93, Aug. 2017, doi: 10.1186/s40168-017-0313-3.
[26] M. B. Dhudasia et al., “Intrapartum Group B Streptococcal Prophylaxis and Childhood Allergic Disorders,” Pediatrics, vol. 147, no. 5, p. e2020012187, May 2021, doi: 10.1542/peds.2020-012187.
[27] K. Dowhower Karpa et al., “A retrospective chart review to identify perinatal factors associated with food allergies,” Nutr. J., vol. 11, p. 87, Oct. 2012, doi: 10.1186/1475-2891-11-87.
[28] D. L. Wohl, W. J. Curry, D. Mauger, J. Miller, and K. Tyrie, “Intrapartum antibiotics and childhood atopic dermatitis,” J. Am. Board Fam. Med. JABFM, vol. 28, no. 1, pp. 82–89, Feb. 2015, doi: 10.3122/jabfm.2015.01.140017.
[29] S. Mukhopadhyay et al., “Intrapartum group B Streptococcal prophylaxis and childhood weight gain,” Arch. Dis. Child. Fetal Neonatal Ed., vol. 106, no. 6, pp. 649–656, Nov. 2021, doi: 10.1136/archdischild-2020-320638.
[30] T. D. Metz, J. McKinney, A. A. Allshouse, S. D. Knierim, J. C. Carey, and K. D. Heyborne, “Exposure to group B Streptococcal antibiotic prophylaxis and early childhood body mass index in a vaginal birth cohort,” J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet., vol. 33, no. 19, pp. 3318–3323, Oct. 2020, doi: 10.1080/14767058.2019.1571575.